Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Oral Orforglipron in Adults With Type 2 Diabetes Inadequately Controlled on Insulin Glargine
jRCT2031230504Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change from Baseline in Hemoglobin A1c (HbA1c) for Orforglipron Dose 1 and Change from Baseline in Hemoglobin A1c (HbA1c) for Orforglipron Dose 2. Started Jan 2024; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031230504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230504.